Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

332
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

907
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

877
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
Gene Therapy00:59

Gene Therapy

27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

963
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tolvaptan can improve clinical course in responders.

International heart journalยท2013
Same author

Insufficient self-care is an independent risk factor for adverse clinical outcomes in Japanese patients with heart failure.

International heart journalยท2013
Same author

Endovascular aortic repair increases vascular stiffness and alters cardiac structure and function.

Circulation journal : official journal of the Japanese Circulation Societyยท2013
Same author

A novel channelopathy in pulmonary arterial hypertension.

The New England journal of medicineยท2013
Same author

High incidence of Aggregatibacter actinomycetemcomitans infection in patients with cerebral infarction and diabetic renal failure: a cross-sectional study.

BMC infectious diseasesยท2013
Same author

Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis.

Modern rheumatologyยท2013

Related Experiment Video

Updated: Jan 31, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

[Gene therapy for heart failure].

Masashi Ohtsuka1, Issei Komuro

  • 1Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.

Nihon Geka Gakkai Zasshi
|October 22, 2002
PubMed
Summary

Gene therapy offers a promising alternative for severe heart failure when conventional treatments fail. Research shows targeted gene transfer can address molecular defects, improving heart function.

Area of Science:

  • Cardiovascular Medicine
  • Molecular Biology
  • Genetics

Context:

  • Conventional treatments for heart failure, including pharmacological, device, and surgical therapies, have limitations, particularly in severe cases.
  • Recent advancements have elucidated key molecular pathways involved in heart failure pathogenesis.
  • Gene therapy is emerging as a potential alternative for managing severe heart failure.

Purpose:

  • To explore the potential of gene therapy as a viable treatment for heart failure.
  • To highlight the importance of understanding molecular pathways for developing targeted gene transfer strategies.
  • To review promising gene transfer modalities for heart failure management.

Summary:

  • Gene therapy is a potential alternative for severe heart failure where conventional therapies are insufficient.

More Related Videos

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.2K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K

Related Experiment Videos

Last Updated: Jan 31, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart
06:07

Large Animal Model for Evaluating the Efficacy of the Gene Therapy in Ischemic Heart

Published on: September 2, 2021

2.2K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
  • Understanding molecular pathways is crucial for developing customized gene transfer strategies.
  • Modulating calcium homeostasis, beta-adrenergic receptor signaling, and cardiomyocyte apoptosis resistance are identified as key therapeutic targets for gene transfer.

    • Impact:

    • Gene therapy offers a novel therapeutic avenue for patients with severe heart failure.
    • Targeted gene transfer strategies can address specific molecular defects underlying heart failure.
    • This approach holds promise for improving treatment outcomes and patient prognosis in heart failure.